

ASX RELEASE

8 November 2018

KAZIA ANNUAL GENERAL MEETING RESULTS

Sydney, 8 November 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Annual General Meeting of shareholders.

All resolutions were carried. The vote totals are attached.

Kazia Chairman, Iain Ross, commented “we are very pleased to have such an emphatic vote of confidence from our shareholders as the company moves forward. Almost 40% of the issued share capital was voted in this AGM, which is an extremely high turnout, and each of the resolutions were passed by a very decisive margin, with approximately 90% of shares voted in favour of each resolution. Kazia has an exciting year ahead, with four value-driving data read-outs from human trials expected, and we continue to be grateful for the support of our investors.”

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

For personal use only

8 November 2018

The Chairman
Kazia Therapeutics Limited
Three International Towers
Level 24
300 Barangaroo Avenue
Sydney, NSW 2000

Poll Report

I, the Returning Officer appointed by you in connection with the voting by poll on the motions set out below at the 2018 Annual General Meeting of the Shareholders of Kazia Therapeutics Limited held at K&L Office, Level 31, 1 O'Connell Street, Sydney NSW on 08 November 2018 at 10:00 am, report as follows:

1 Adoption of Remuneration Report

	Number	%
Votes cast 'FOR' the motion	20,311,895	89.75
Votes cast 'AGAINST' the motion	2,318,715	10.25
TOTAL VOTES CAST	<u>22,630,610</u>	<u>100.00</u>
Votes "Abstained"	216,839	

The resolution was carried as an ordinary resolution.

2 Re-election of Iain Ross

	Number	%
Votes cast 'FOR' the motion	21,071,116	90.49
Votes cast 'AGAINST' the motion	2,214,969	9.51
TOTAL VOTES CAST	<u>23,286,085</u>	<u>100.00</u>
Votes "Abstained"	65,183	

The resolution was carried as an ordinary resolution.

For personal use only

Approval of Additional Placement

	Number	%
Votes cast 'FOR' the motion	20,597,110	88.53
Votes cast 'AGAINST' the motion	2,669,288	11.47
TOTAL VOTES CAST	<u>23,266,398</u>	<u>100.00</u>
Votes "Abstained"	84,870	

The resolution was carried as a special resolution.



Justine Laughton
Returning Officer
Computershare Investor Services Pty Limited

For personal use only